Evoked pain analgesia in chronic pelvic pain patients using respiratory-gated auricular vagal afferent nerve stimulation
V Napadow, RR Edwards, CM Cahalan… - Pain …, 2012 - academic.oup.com
Pain medicine, 2012•academic.oup.com
Objective. Previous vagus nerve stimulation (VNS) studies have demonstrated
antinociceptive effects, and recent noninvasive approaches, termed transcutaneous-vagus
nerve stimulation (t-VNS), have utilized stimulation of the auricular branch of the vagus
nerve in the ear. The dorsal medullary vagal system operates in tune with respiration, and
we propose that supplying vagal afferent stimulation gated to the exhalation phase of
respiration can optimize t-VNS. Design. Counterbalanced, crossover study. Patients …
antinociceptive effects, and recent noninvasive approaches, termed transcutaneous-vagus
nerve stimulation (t-VNS), have utilized stimulation of the auricular branch of the vagus
nerve in the ear. The dorsal medullary vagal system operates in tune with respiration, and
we propose that supplying vagal afferent stimulation gated to the exhalation phase of
respiration can optimize t-VNS. Design. Counterbalanced, crossover study. Patients …
Abstract
Objective. Previous vagus nerve stimulation (VNS) studies have demonstrated antinociceptive effects, and recent noninvasive approaches, termed transcutaneous-vagus nerve stimulation (t-VNS), have utilized stimulation of the auricular branch of the vagus nerve in the ear. The dorsal medullary vagal system operates in tune with respiration, and we propose that supplying vagal afferent stimulation gated to the exhalation phase of respiration can optimize t-VNS.
Design. Counterbalanced, crossover study.
Patients. Patients with chronic pelvic pain (CPP) due to endometriosis in a specialty pain clinic.
Interventions/Outcomes. We evaluated evoked pain analgesia for respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) compared with nonvagal auricular stimulation (NVAS). RAVANS and NVAS were evaluated in separate sessions spaced at least 1 week apart. Outcome measures included deep-tissue pain intensity, temporal summation of pain, and anxiety ratings, which were assessed at baseline, during active stimulation, immediately following stimulation, and 15 minutes after stimulus cessation.
Results. RAVANS demonstrated a trend for reduced evoked pain intensity and temporal summation of mechanical pain, and significantly reduced anxiety in N = 15 CPP patients, compared with NVAS, with moderate to large effect sizes (η2 > 0.2).
Conclusion. Chronic pain disorders such as CPP are in great need of effective, nonpharmacological options for treatment. RAVANS produced promising antinociceptive effects for quantitative sensory testing (QST) outcomes reflective of the noted hyperalgesia and central sensitization in this patient population. Future studies should evaluate longer-term application of RAVANS to examine its effects on both QST outcomes and clinical pain.
Oxford University Press